CDC has issued an HAN Health Alert on Seoul Virus, a hantavirus, which can be contracted from pet rates and can result in potentially fatal Hemorrhagic Fever with Renal Syndrome (HFRS). The primary source of the Virus in the US is in the Midwest, but infected rats have been found in much of the US.
Seoul virus is transmitted from rats to people. People who become infected with this virus often exhibit relatively mild or no symptoms, but some develop HFRS (https://www.cdc.gov/hantavirus/hfrs), which can result in death in approximately 1–2% of HFRS cases. Symptoms include fever, severe headache, back and abdominal pain, chills, blurred vision, redness of the eyes, or rash. HFRS is characterized by a prodromal phase with non-specific symptoms and can progress to hypotension, decreased urine output, and renal failure, which often resolves after a diuretic phase. Coagulopathy and pulmonary edema are rare complications. Laboratory findings include low platelets, elevated white blood cell counts, electrolyte abnormalities, elevated blood urea nitrogen (BUN) and creatinine, and proteinuria. Find the HAN notice at https://emergency.cdc.gov/han/han00400.asp .
The FDA has issued a warning about malfunction of Implantable Infusion Pumps that are, or have been, exposed to high-EMF environments such as MRI machines. For details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm536526.htm .
The FDA has issued an expanded warning label about type 2 diabetes medications containing Pioglitazone, which includes Actos, Actoplus Met, Actoplus Met XR, Duetact, and Oseni. The FDA has concluded that Pioglitazone does increase the risk of bladder cancer, and recommends that it not be prescribed for patients with bladder cancer, and that all others using it watch for blood or a red color in the urine, new or worsening urge to urinate, or pain when urinating, any of which could indicate possible bladder cancer. For full details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm532772.htm .
The FDA has warned that Direct-Acting Antivirals for Hepatitis C can in some cases encourage the growth or regrowth of Hepatitis B, possibly resulting in serious injury or death. Find the Drug Safety Announcement, including a list of Direct-Acting Antivirals, at http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm , and more information at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm523690.htm .
CDC has changed their recommendations for the administration of flu vaccine to people with egg allergies. For details see http://www.cdc.gov/flu/protect/vaccine/egg-allergies.htm .
The FDA has added a searchable online real-time database to their Drug Safety Labeling Changes notification, which till now has been a monthly summary via email. Find the search window at http://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/ and an announcement of the service at http://www.fda.gov/Drugs/DrugSafety/ucm517519.htm . A new email notification option is also available, via a link on the search window.
The FDA is warning healthcare providers who use Programmable Syringe Pumps from any manufacturer, that the FDA has been advised of many adverse events resulting from inconsistent delivery of therapeutic fluids when used at flow rates of less than 5 mL per hour, and especially at rates less than 0.5 mL per hour. Find details and FDA recommendations at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm518074.htm .